Accordingly, LSD1 has been proposed as a selective epigenetic target for therapy in SOX2-expressing cancers, particularly in those carcinomas in which high SOX2 expression occurs via 3q26 chromosomal amplification (e.g., lung SCLC, serous ovarian carcinoma, cervical, head and neck, oral, and esophageal carcinomas [6]). Here, SOX2 is linked to carcinoma of esophagus.